Skip Navigation

European Heart Journal 2002 23(3):207-215; doi:10.1053/euhj.2001.2775
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (38)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Simes, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simes, J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project

J Simesa,f1, C.D Furbergb, E Braunwaldc, B.R Davisd, I Forde, A Tonkinf and J Shepherde for the Prosective Pravastatin Pooling project investigators

a University of Sydney, Sydney, Australia
b Wake Forest University, Winston-Salem, NC, U.S.A.
c Brigham and Women's Hospital, Boston, Mass. U.S.A.
d University of Texas School of Public Health, Houston, Texas
e University of Glasgow, Glasgow, Scotland
f National Heart Foundation, Melbourne, Australia

revised May 1, 2001; accepted May 2, 2001

Abstract

Aims To assess the effects of pravastatin on all-cause mortality and cause-specific mortality and to compare the effects for patients with prior coronary heart disease with those for patients without, using pooled data from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study, the Cholesterol and Recurrent Events (CARE) study, and the West of Scotland Coronary Prevention Study (WOSCOPS).

Methods and Results 13173 patients with coronary heart disease and 6595 men with elevated cholesterol and no prior coronary disease received pravastatin, 40mg daily, or placebo for an average of 5 to 6 years. Data were analysed according to a pre-specified, published protocol. For all three trials combined, the mortality among patients assigned pravastatin was significantly lower, at 7·9%, than the 9·8% among those assigned placebo, a relative risk reduction of 20% (95% confidence interval (CI) 12–27%, P<0·0001). Active treatment was associated with a reduction in coronary mortality (24%, 95% CI 14–33%). Larger reductions in absolute risk were estimated in those with prior coronary heart disease than in those without.

Conclusion Treatment with pravastatin over 5 years reduces all-cause mortality and coronary mortality in patients with and those without a history of coronary heart disease. The size of the benefit was related principally to the baseline risk.

Key Words: Lipids, mortality, meta-analysis, clinical trial, coronary disease, cholesterol

f1 Correspondence: Professor John Simes, NHMRC Clinical Trials Centre, Mallett Street Campus, University of Sydney, NSW 2006, Australia.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Gen. Virol.Home page
V. Vetrugno, M. A. Di Bari, R. Nonno, M. Puopolo, C. D'Agostino, L. Pirisinu, M. Pocchiari, and U. Agrimi
Oral pravastatin prolongs survival time of scrapie-infected mice
J. Gen. Virol., July 1, 2009; 90(7): 1775 - 1780.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
N K Wenger, S J Lewis, F K Welty, D M Herrington, V Bittner, and on behalf of the TNT Steering Committee and Invest
Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study
Heart, April 1, 2008; 94(4): 434 - 439.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
M. Terblanche, N. K.J. Adhikari, and D. C. Scales
Does {beta}-blocker prophylaxis improve survival after major noncardiac surgery?
Can. Med. Assoc. J., October 11, 2005; 173(8): 874 - 874.
[Full Text] [PDF]

Home page
 CirculationHome page
R. A.H. Stewart, H. D. White, A. C. Kirby, S. R. Heritier, R. J. Simes, P. J. Nestel, M. J. West, D. M. Colquhoun, A. M. Tonkin, and for the Long-Term Intervention With Pravastatin in
White Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin
Circulation, April 12, 2005; 111(14): 1756 - 1762.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. Genest and T. R. Pedersen
Prevention of Cardiovascular Ischemic Events: High-Risk and Secondary Prevention
Circulation, April 22, 2003; 107(15): 2059 - 2065.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
F. M. Sacks
Low-density lipoprotein lowering therapy: an analysis of the options
J. Am. Coll. Cardiol., December 18, 2002; 40(12): 2135 - 2138.
[Full Text] [PDF]

Home page
 CirculationHome page
M. A. Pfeffer, A. Keech, F. M. Sacks, S. M. Cobbe, A. Tonkin, R. P. Byington, B. R. Davis, C. P. Friedman, and E. Braunwald
Safety and Tolerability of Pravastatin in Long-Term Clinical Trials: Prospective Pravastatin Pooling (PPP) Project
Circulation, May 21, 2002; 105(20): 2341 - 2346.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
J. Muntwyler and F. Gutzwiller
Statins and mortality
Eur. Heart J., February 1, 2002; 23(3): 183 - 184.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.